Conclusions: Many mBC patients initiating IV paclitaxel/nab-paclitaxel experienced dose reductions, toxicities, and/or early discontinuation of the Index LOT, which may limit treatment effectiveness.

For many people with cancer, intravenous (IV) infusions of chemotherapy are their best chance at a cure. But these infusions can be inconvenient or inaccessible to patients, and some complications ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

Purpose Intraperitoneal (IP) cisplatin and intravenous (IV) or IP paclitaxel constitute a standard therapy for optimally debulked ovarian cancer. Bevacizumab prolongs progression-free survival (PFS) ...

The single-dose 100 mg vial for intravenous use is approved for metastatic breast cancer.

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral disease.

Topline data were announced from a phase 2/3 trial evaluating tovecimig plus paclitaxel in patients with advanced biliary tract cancer.

Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Two major side-effects of paclitaxel therapy are frequent hypersensitivity reactions and neuropathy.

Liporaxel demonstrated non-inferiority in progression-free survival and superiority in overall survival compared to intravenous paclitaxel as a second-line therapy for patients with advanced gastric ...

Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical ...